Nuformix Past Earnings Performance
Past criteria checks 0/6
Nuformix has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been declining at an average rate of 60.4% per year.
Key information
16.1%
Earnings growth rate
26.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | -60.4% |
| Return on equity | -13.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nuformix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 2 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 1 | -1 | 1 | 0 |
| 31 Dec 19 | 1 | -1 | 1 | 0 |
| 30 Sep 19 | 1 | -1 | 1 | 0 |
| 30 Jun 19 | 1 | -1 | 1 | 0 |
| 31 Mar 19 | 1 | -2 | 1 | 0 |
| 31 Dec 18 | 1 | -2 | 1 | 0 |
| 30 Sep 18 | 1 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Mar 16 | 1 | 0 | 0 | 0 |
| 31 Jul 15 | 0 | 0 | 0 | 0 |
| 31 Jul 14 | 0 | 0 | 0 | 0 |
Quality Earnings: NFX is currently unprofitable.
Growing Profit Margin: NFX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NFX is unprofitable, but has reduced losses over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare NFX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NFX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: NFX has a negative Return on Equity (-13.66%), as it is currently unprofitable.